A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Miransertib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors ArQule
- 03 Nov 2016 Status changed from active, no longer recruiting to completed, as reported in an ArQule media release.
- 02 May 2016 Planned number of patients changed from 132 to 125.
- 02 May 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History